These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25204805)

  • 1. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer.
    Assayag J; Pollak MN; Azoulay L
    Eur J Cancer; 2014 Nov; 50(16):2838-45. PubMed ID: 25204805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
    Grytli HH; Fagerland MW; Fosså SD; Taskén KA
    Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of statins and the risk of death in patients with prostate cancer.
    Yu O; Eberg M; Benayoun S; Aprikian A; Batist G; Suissa S; Azoulay L
    J Clin Oncol; 2014 Jan; 32(1):5-11. PubMed ID: 24190110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of metformin in patients with prostate cancer and the risk of death.
    Bensimon L; Yin H; Suissa S; Pollak MN; Azoulay L
    Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):2111-8. PubMed ID: 25017246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of aspirin and the risk of mortality in patients with prostate cancer.
    Assayag J; Pollak MN; Azoulay L
    J Urol; 2015 Apr; 193(4):1220-5. PubMed ID: 25463991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
    Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
    Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study.
    Shireman TI; Mahnken JD; Phadnis MA; Ellerbeck EF
    BMC Cardiovasc Disord; 2016 Mar; 16():60. PubMed ID: 27012911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.
    Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
    Cancer; 2007 Mar; 109(6):1192-202. PubMed ID: 17311344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
    Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
    Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 diabetes and the risk of mortality among patients with prostate cancer.
    Bensimon L; Yin H; Suissa S; Pollak MN; Azoulay L
    Cancer Causes Control; 2014 Mar; 25(3):329-38. PubMed ID: 24384808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cohort study of digoxin exposure and mortality in men with prostate cancer.
    Flahavan EM; Sharp L; Bennett K; Barron TI
    BJU Int; 2014 Feb; 113(2):236-45. PubMed ID: 23937513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
    Azoulay L; Eberg M; Benayoun S; Pollak M
    JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical activity and survival among men diagnosed with prostate cancer.
    Bonn SE; Sjölander A; Lagerros YT; Wiklund F; Stattin P; Holmberg E; Grönberg H; Bälter K
    Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):57-64. PubMed ID: 25527697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
    Margel D; Urbach DR; Lipscombe LL; Bell CM; Kulkarni G; Austin PC; Fleshner N
    J Clin Oncol; 2013 Sep; 31(25):3069-75. PubMed ID: 23918942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index and mortality in men with prostate cancer.
    Cantarutti A; Bonn SE; Adami HO; Grönberg H; Bellocco R; Bälter K
    Prostate; 2015 Aug; 75(11):1129-36. PubMed ID: 25929695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index and weight change in men with prostate cancer: progression and mortality.
    Bonn SE; Wiklund F; Sjölander A; Szulkin R; Stattin P; Holmberg E; Grönberg H; Bälter K
    Cancer Causes Control; 2014 Aug; 25(8):933-43. PubMed ID: 24810654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study.
    Holmes S; Griffith EJ; Musto G; Minuk GY
    Cancer Epidemiol; 2013 Dec; 37(6):881-5. PubMed ID: 24075077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.
    Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
    Cancer Causes Control; 2008 Feb; 19(1):25-31. PubMed ID: 17906959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel use and cancer-specific mortality: a population-based cohort study of colorectal, breast and prostate cancer patients.
    Hicks BM; Murray LJ; Hughes C; Cardwell CR
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):830-40. PubMed ID: 26017274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women.
    Botteri E; Munzone E; Rotmensz N; Cipolla C; De Giorgi V; Santillo B; Zanelotti A; Adamoli L; Colleoni M; Viale G; Goldhirsch A; Gandini S
    Breast Cancer Res Treat; 2013 Aug; 140(3):567-75. PubMed ID: 23912960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.